Extraction of Myxopyronin A antibiotic from different soil environments in Egypt

Background: Across the world, antibiotic resistance is a terrible problem. To address this issue, it is necessary to investigate new antibiotic sources. Aim of the study: Egyptian soil settings were used to produce the antibiotic Myxopyronin A, which was then tested for antibacterial activity in preclinical animal testing and phase 1/2 randomized human clinical trials. Type of the study: Screening experimental work. Methodology: In order to find bacterial isolates that may produce the antibiotic compound Myxopyronin A, several soil conditions in Egypt were examined. HPLC in the reversed-phase was used to purify Myxopyronin A. The test antibiotic's minimum inhibitory concentration (MIC) and invitro antibacterial activity were determined using the paper disc diffusion assay and the broth dilution method. Additionally, adverse medication responses, pharmacokinetics, and the in vivo antimicrobial spectrum were identified throughout the testing phases of animal models and human randomized clinical trials. Results: Myxopyronin A was generated from the culture supernatant of Myxococcus fulvus 124B02 , the main soil bacterial isolate cultured on Casein yeast peptone plate. With MICs less than 100 mcg/ml, the test antibiotic prevented the growth of several Gram +ve bacteria, whereas at MICs higher than 100 mcg/ml, it inhibited the growth of a small number of Gram -ve bacteria, including Escherichia coli . However, eukaryotic cells—such as those found in fungi and humans—were unaffected. The test antibiotic was seen to inhibit prokaryotic DNA-dependent RNA polymerase (RNLP), indicating its bactericidal activity. Phases 1/2 of randomized human clinical studies showed that when the 600 mg dose was given orally, the maximal concentration was 7-8 mcg/ml at a maximum duration of 2 hours; T1/2 also reached 2.5 hours. It did, however, adhere to first-order kinetics of elimination. After being taken orally, the test antibiotic took more than 12 hours to act. During phases 1/2 of preclinical and randomized human clinical trials, uncommon toxicity that caused mild diarrhea and cholestatic jaundice occurred in fewer than 5% of experimental applicants. Conclusion: The current study was encouraging since Myxococcus fulvus 124B02 , isolated from several soil habitats in Egypt, generated the bactericidal antibiotic Myxopyronin A. It took part in Egypt's victory against bacterial resistance.